Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Immutep ( (IMMP) ).
In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer after an interim futility analysis showed patients on eftilagimod alfa with KEYTRUDA and chemotherapy underperformed the placebo combination, prompting a full wind-down and a detailed root cause review. Despite this setback, other efti studies, including INSIGHT-003 in NSCLC and EFTISARC-NEO in soft tissue sarcoma, have reported encouraging response and immune-activation data, and efti received U.S. orphan drug designation for neoadjuvant soft tissue sarcoma in April 2026.
The company is also advancing its IMP761 autoimmune program, with a Phase I trial showing a favourable safety profile up to 14 mg/kg and now progressing into a multiple ascending dose phase, with key data to be presented at the EULAR 2026 congress. Financially, Immutep ended 31 March 2026 with A$110.6 million in cash, cash equivalents and term deposits, bolstered by a US$20 million upfront payment from Dr. Reddy’s, supporting operations and the TACTI-004 wind-down while it reassesses the broader efti development strategy.
The most recent analyst rating on (IMMP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Underperform.
The score is primarily held down by weak financial performance, including persistent losses and negative operating/free cash flow. Technicals add further pressure due to a broader downtrend and negative MACD, though near-oversold RSI/Stoch modestly offsets this. Valuation is also constrained by a negative P/E and no dividend yield data.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a Sydney-based clinical-stage biotechnology company focused on developing immunotherapies targeting LAG-3 for cancer and autoimmune diseases. Its lead asset, eftilagimod alfa, is being tested across multiple oncology indications, while IMP761 is a first-in-class LAG-3 agonist antibody aimed at treating autoimmune conditions. The company operates globally via partnerships, including a key licensing deal with Dr. Reddy’s Laboratories.
Average Trading Volume: 15,413,575
Technical Sentiment Signal: Sell
Current Market Cap: $62.62M
See more insights into IMMP stock on TipRanks’ Stock Analysis page.